IRIS UniCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.267
EU - Europa 1.127
AS - Asia 561
SA - Sud America 64
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 3.059
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.230
IT - Italia 219
SG - Singapore 219
SE - Svezia 204
FR - Francia 160
CN - Cina 154
PL - Polonia 115
DE - Germania 114
IN - India 71
IE - Irlanda 62
BR - Brasile 52
GB - Regno Unito 51
ID - Indonesia 44
FI - Finlandia 38
RU - Federazione Russa 28
ES - Italia 26
UA - Ucraina 26
CA - Canada 18
MX - Messico 16
BE - Belgio 13
AT - Austria 12
PT - Portogallo 12
KR - Corea 11
PH - Filippine 11
HK - Hong Kong 10
LT - Lituania 10
ZA - Sudafrica 9
CM - Camerun 8
NL - Olanda 8
IR - Iran 7
RO - Romania 7
TW - Taiwan 6
CH - Svizzera 5
CL - Cile 5
GR - Grecia 5
TR - Turchia 5
CI - Costa d'Avorio 4
CO - Colombia 4
EU - Europa 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
DZ - Algeria 3
JP - Giappone 3
TH - Thailandia 3
UG - Uganda 3
AR - Argentina 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
HR - Croazia 2
IQ - Iraq 2
NG - Nigeria 2
TN - Tunisia 2
AM - Armenia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
EC - Ecuador 1
HN - Honduras 1
IL - Israele 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
VN - Vietnam 1
Totale 3.059
Salva come PNG Salva come JPEG
Città #
Chandler 320
Singapore 132
Kraków 108
Ashburn 79
New York 73
Milan 62
Dublin 61
Jakarta 42
Jacksonville 40
Redmond 36
San Mateo 36
Rome 28
Boston 27
Wilmington 26
Princeton 24
Ann Arbor 23
Paris 23
Beijing 22
Marseille 22
Cattolica 21
Helsinki 21
London 19
Moscow 19
Nanjing 19
Los Angeles 17
Pune 17
Redwood City 17
Dearborn 16
Houston 15
Catania 14
Frankfurt am Main 13
Madrid 13
Brussels 12
Seattle 11
Nanchang 10
Fairfield 9
Norwalk 9
Vienna 9
Düsseldorf 8
Lawrence 8
Nuremberg 8
Ottawa 8
Woodbridge 8
Bremen 7
Changsha 7
Chicago 7
The Dalles 7
Cusano Milanino 6
Davao City 6
Hebei 6
Turin 6
Washington 6
Boardman 5
Bucharest 5
La Habra 5
Lancaster 5
Mountain View 5
Shenyang 5
Amsterdam 4
Bologna 4
Council Bluffs 4
Edinburgh 4
Florence 4
Fuzhou 4
Hangzhou 4
Hefei 4
Hong Kong 4
Hyderabad 4
Jiaxing 4
Kempton Park 4
Lappeenranta 4
Lauterbourg 4
Lisbon 4
Nürnberg 4
Portsmouth 4
Santiago 4
Suyeong-gu 4
Tianjin 4
Toronto 4
Atlanta 3
Aversa 3
Cambridge 3
Dallas 3
Dubai 3
Georgetown 3
Guadalupe 3
Guangzhou 3
Jinan 3
Kish 3
Kunming 3
Livorno 3
Longarone 3
Manchester 3
Manila 3
North Bergen 3
San Francisco 3
Seoul 3
Stockholm 3
Surrey 3
Taipei 3
Totale 1.740
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 384
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 145
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 143
Cognitive reserve and neuropsychological functioning in older HIV-infected people 110
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 106
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 103
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 100
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 94
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 91
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 90
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 87
Whole-genome sequencing reveals host factors underlying critical COVID-19 85
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 85
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 85
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 79
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 73
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 69
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 68
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 66
An explainable model of host genetic interactions linked to COVID-19 severity 64
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 63
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 63
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 61
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 59
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 58
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 57
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 56
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 56
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 53
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 49
Treatment of HCV infection with the novel NS3/4A protease inhibitors 48
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 43
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 40
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 37
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 37
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 36
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 35
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 32
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 26
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 24
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 20
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 19
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 16
Totale 3.115
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.115
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202096 0 0 0 0 0 0 0 0 0 0 88 8
2020/2021106 23 11 4 5 12 8 6 2 13 6 12 4
2021/2022269 12 3 4 19 7 12 13 53 10 27 34 75
2022/2023887 96 105 53 116 61 100 32 77 101 70 58 18
2023/2024567 27 108 28 40 36 126 31 25 24 24 39 59
2024/2025643 30 40 91 52 106 43 52 50 99 71 9 0
Totale 3.115